IP Library › Granted Patent US 12,109,205
Granted Patent B2
US 12,109,205 · App. 17/078,840 · Granted Oct 8, 2024

Methods of treating Fabry patients having renal impairment

Inventors: Jeff Castelli (New Hope, PA); Elfrida Benjamin (Millstone Township, NJ)
Assignee: Amicus Therapeutics, Inc.
A61K31/445A61P13/12A61K9/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,109,205
App. No.
17/078,840
Granted
Oct 8, 2024
Kind
B2
Abstract

Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.

Claims (98)

1. A method of treating Fabry disease, the method comprising administering migalastat to a patient in need thereof, wherein the patient has an α-galactosidase A protein comprising a HEK assay amenable mutation selected from the group consisting of: R4M/Y207S, A15T, A15G, F18C, W24G, N34D, G35V, M42I, E48Q, N53D, P60S, F69L, M721, G85S, G85N, G104V, L106F, A108T, D109G, R112G, G144D, L167V, L180W, G195V, R196G, V199A, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, G271S/D313Y, W277C, D299E, S304T, D313Y/G411D, I319F, F337S, P343L, G361A, P362T, K391T, G395E and p.T400_S401dup.

2. The method of claim 1 , wherein the mutation is selected from the group consisting of: A15T, F18C, W24G, G35V, M42I, N53D, P60S, F69L, M72I, G104V, L106F, A108T, G144D, L167V, L180W, G195V, R196G, V199A, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T and K391T.

3. The method of claim 1 , wherein the mutation is selected from the group consisting of: N53D, P60S, L180W, R196G, P210S, P210L, P214S, R220P, Q221P, I242T, Q250H, p.V254del, G260E, G261S, D299E, S304T and P362T.

4. The method of claim 1 , wherein the mutation is selected from the group consisting of: R4M/Y207S, A15T, A15G, W24G, G35V, M42I, E48Q, N53D, P60S, F69L, M72I, G85S, G85N, G104V, L106F, A108T, D109G, G144D, L167V, L180W, G195V, R196G, V199A, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T, K391T, G395E and p.T400_S401dup.

5. The method of claim 1 , wherein the mutation is selected from the group consisting of: R4M/Y207S, W24G, G35V, M421, E48Q, N53D, P60S, F69L, G85S, G85N, G104V, L106F, D109G, G144D, L180W, G195V, R196G, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T, K391T, G395E and p.T400_S401dup.

6. The method of claim 1 , wherein the mutation is selected from the group consisting of: G35V, M421, F69L and L180W.

7. The method of claim 1 , wherein the mutation is selected from the group consisting of: A15T, W24G, G35V, M42I, N53D, P60S, F69L, M72I, G104V, L106F, A108T, G144D, L167V, L180W, G195V, R196G, V199A, P210S, P210L, P214S, R220P Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T and K391T.

8. The method of claim 1 , wherein the mutation is selected from the group consisting of: W24G, G35V, M42I, N53D, P60S, F69L, G104V, L106F, G144D, L180W, G195V, R196G, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T and K391T.

9. The method of claim 1 , wherein the mutation is selected from the group consisting of: R4M/Y207S, A15T, A15G, F18C, W24G, N34D, G35V, M42I, E48Q, N53D, P60S, F69L, M72I, G85S, G85N, G104V, L106F, A108T, D109G, R112G, G144D, L167V, L180W, G195V, R196G, V199A, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, G260E, G261S, G271S/D313Y, W277C, D299E, S304T, D313Y/G411D, I319F, F337S, P343L, G361A, P362T, K391T and G395E.

10. The method of claim 1 , wherein the mutation is selected from the group consisting of: R4M/Y207S, W24G, G35V, M42I, E48Q, N53D, P60S, F69L, G85S, G85N, G104V, L106F, D109G, G144D, L180W, G195V, R196G, E203D, P210S, P210L, P2145, R220P, Q221P, F229L, I242T, Q250H, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T, K391T and G395E.

11. The method of claim 1 , wherein the mutation is selected from the group consisting of: A15T, F18C, W24G, G35V, M42I, N53D, P60S, F69L, M72I, G104V, L106F, A108T, G144D, L167V, L180W, G195V, R196G, V199A, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T and K391T.

12. The method of claim 1 , wherein the mutation is selected from the group consisting of: N53D, P60S, L180W, R196G, P210S, P210L, P214S, R220P, Q221P, I242T, Q250H, G260E, G261S, D299E, S304T and P362T.

13. The method of claim 1 , wherein the mutation is selected from the group consisting of: W24G, G35V, M42I, N53D, P60S, F69L, G104V, L106F, G144D, L180W, G195V, R196G, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T and K391T.

14. The method of claim 1 , wherein the patient has a Fabry disease-causing mutation.

15. The method of claim 1 , wherein the migalastat or salt thereof is administered to the patient every other day.

16. The method of claim 1 , wherein the patient is administered about 123 to about 300 mg of the migalastat or salt thereof every other day.

17. The method of claim 1 , wherein the patient is administered about 150 mg of the migalastat or salt thereof every other day.

18. The method of claim 1 , wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

19. The method of claim 1 , wherein the patient is male.

20. The method of claim 1 , wherein the patient is female.

21. The method of claim 1 , wherein the patient has renal impairment.

22. The method of claim 21 , wherein the patient has mild or moderate renal impairment.

23. The method of claim 1 , wherein the patient is an enzyme replacement therapy (ERT)-experienced patient.

24. The method of claim 1 , wherein the patient is an enzyme replacement therapy (ERT)-experienced patient with renal impairment.

25. The method of claim 1 , wherein the patient is an enzyme replacement therapy (ERT)-naïve patient.

26. The method of claim 1 , wherein the patient has a proteinuria level of less than 100 mg/24 hr prior to initiating the administration of the migalastat or salt thereof.

27. The method of claim 1 , wherein the patient has a proteinuria level of 100 to 1,000 mg/24 hr prior to initiating the administration of the migalastat or salt thereof.

28. The method of claim 1 , wherein the patient has a proteinuria level of greater than 1,000 mg/24 hr prior to initiating the administration of the migalastat or salt thereof.

29. The method of claim 1 , wherein the migalastat or salt thereof is administered orally.

30. The method of claim 29 , wherein the migalastat or salt thereof is in a solid dosage form.

31. The method of claim 30 , wherein the solid dosage form comprises a capsule.

32. The method of claim 1 , wherein the migalastat is administered as a pharmaceutically acceptable salt.

33. The method of claim 1 , wherein the patient is orally administered a capsule comprising about 150 mg of migalastat hydrochloride every other day.

34. The method of claim 8 , wherein the patient has a Fabry disease-causing mutation.

35. The method of claim 8 , wherein the migalastat or salt thereof is administered to the patient every other day.

36. The method of claim 8 , wherein the patient is administered about 123 to about 300 mg of the migalastat or salt thereof every other day.

37. The method of claim 8 , wherein the patient is administered about 150 mg of the migalastat or salt thereof every other day.

38. The method of claim 8 , wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

39. The method of claim 8 , wherein the patient is male.

40. The method of claim 8 , wherein the patient is female.

41. The method of claim 8 , wherein the patient has renal impairment.

42. The method of claim 41 , wherein the patient has mild or moderate renal impairment.

43. The method of claim 8 , wherein the patient is an enzyme replacement therapy (ERT)-experienced patient.

44. The method of claim 8 , wherein the patient is an enzyme replacement therapy (ERT)-experienced patient with renal impairment.

45. The method of claim 8 , wherein the patient is an enzyme replacement therapy (ERT)-naïve patient.

46. The method of claim 8 , wherein the patient has a proteinuria level of less than 100 mg/24 hr prior to initiating the administration of the migalastat or salt thereof.

47. The method of claim 8 , wherein the patient has a proteinuria level of 100 to 1,000 mg/24 hr prior to initiating the administration of the migalastat or salt thereof.

48. The method of claim 8 , wherein the patient has a proteinuria level of greater than 1,000 mg/24 hr prior to initiating the administration of the migalastat or salt thereof.

49. The method of claim 8 , wherein the migalastat or salt thereof is administered orally.

50. The method of claim 49 , wherein the migalastat or salt thereof is in a solid dosage form.

51. The method of claim 50 , wherein the solid dosage form comprises a capsule.

52. The method of claim 8 , wherein the migalastat is administered as a pharmaceutically acceptable salt.

53. The method of claim 8 , wherein the patient is orally administered a capsule comprising about 150 mg of migalastat hydrochloride every other day.

54. The method of claim 1 , wherein the administration is effective to reduce globotriaosylceramide (GL-3) accumulated in an organ of the patient.

55. The method of claim 1 , wherein the administration is effective to reduce plasma globotriaosylsphingosine (lyso-Gb3) in the patient.

56. The method of claim 1 , wherein the administration is effective to increase white blood cell (WBC) α-galactosidase A activity in the patient.

57. The method of claim 1 , wherein the administration is effective to reduce left ventricular mass index (LVMi) in the patient.

58. The method of claim 1 , wherein the administration is effective to stabilize renal function in the patient.

59. The method of claim 1 , wherein the administration is effective to (i) reduce globotriaosylceramide (GL-3) accumulated in an organ of the patient, (ii) reduce plasma globotriaosylsphingosine (lyso-Gb3) in the patient, (iii) increase white blood cell (WBC) α-galactosidase A activity in the patient, (iv) reduce left ventricular mass index (LVMi) in the patient, or (v) stabilize renal function in the patient.

60. A molecule comprising migalastat bound to an a-galactosidase A protein comprising a HEK assay amenable mutation selected from the group consisting of: R4M/Y207S, A15T, A15G, F18C, W24G, N34D, G35V, M42I, E48Q, N53D, P60S, F69L, M721, G85S, G85N, G104V, L106F, A108T, D109G, R112G, G144D, L167V, L180W, G195V, R196G, V199A, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, G271S/D313Y, W277C, D299E, S304T, D313Y/G411D, I319F, F337S, P343L, G361A, P362T, K391T, G395E and p.T400_S401dup.

61. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: A15T, F18C, W24G, G35V, M42I, N53D, P60S, F69L, M72I, G104V, L106F, A108T, G144D, L167V, L180W, G195V, R196G, V199A, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T and K391T.

62. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: N53D, P60S, L180W, R196G, P210S, P210L, P214S, R220P, Q221P, I242T, Q250H, p.V254del, G260E, G261S, D299E, S304T and P362T.

63. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: R4M/Y207S, A15T, A15G, W24G, G35V, M42I, E48Q, N53D, P60S, F69L, M72I, G85S, G85N, G104V, L106F, A108T, D109G, G144D, L167V, L180W, G195V, R196G, V199A, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T, K391T, G395E and p.T400_S401dup.

64. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: R4M/Y207S, W24G, G35V, M421, E48Q, N53D, P60S, F69L, G85S, G85N, G104V, L106F, D109G, G144D, L180W, G195V, R196G, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T, K391T, G395E and p.T400_S401dup.

65. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: G35V, M421, F69L and L180W.

66. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: A15T, W24G, G35V, M421, N53D, P60S, F69L, M721, G104V, L106F, A108T, G144D, L167V, L180W, G195V, R196G, V199A, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T and K391T.

67. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: W24G, G35V, M421, N53D, P60S, F69L, G104V, L106F, G144D, L180W, G195V, R196G, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T and K391T.

68. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: R4M/Y207S, A15T, A15G, F18C, W24G, N34D, G35V, M421, E48Q, N53D, P60S, F69L, M721, G85S, G85N, G104V, L106F, A108T, D109G, R112G, G144D, L167V, L180W, G195V, R196G, V199A, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, G260E, G261S, G271S/D313Y, W277C, D299E, S304T, D313Y/G411D, I319F, F337S, P343L, G361A, P362T, K391T and G395E.

69. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: R4M/Y207S, W24G, G35V, M421, E48Q, N53D, P60S, F69L, G85S, G85N, G104V, L106F, D109G, G144D, L180W, G195V, R196G, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T, K391T and G395E.

70. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: A15T, F18C, W24G, G35V, M42I, N53D, P60S, F69L, M72I, G104V, L106F, A108T, G144D, L167V, L180W, G195V, R196G, V199A, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T and K391T.

71. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: N53D, P60S, L180W, R196G, P210S, P210L, P214S, R220P, Q221P, I242T, Q250H, G260E, G261S, D299E, S304T and P362T.

72. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: W24G, G35V, M42I, N53D, P60S, F69L, G104V, L106F, G144D, L180W, G195V, R196G, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T and K391T.

73. An α-galactosidase A protein having a HEK amenable mutation selected from the group consisting of: R4M/Y207S, A15T, A15G, F18C, W24G, N34D, G35V, M42I, E48Q, N53D, P60S, F69L, M72I, G85S, G85N, G104V, L106F, A108T, D109G, R112G, G144D, L167V, L180W, G195V, R196G, V199A, E203D, P210S, P210L, P214S, R220P Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, G271S/D313Y, W277C, D299E, S304T, D313Y/G411D, I319F, F337S, P343L, G361A, P362T, K391T, G395E and p.T400_S401dup,

wherein the protein is bound to migalastat and the protein has increased stability as compared to a naturally-occurring a-galactosidase A protein having the same mutation.

74. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: A15T, F18C, W24G, G35V, M421, N53D, P60S, F69L, M721, G104V, L106F, A108T, G144D, L167V, L180W, G195V, R196G, V199A, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T and K391T.

75. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: N53D, P60S, L180W, R196G, P210S, P210L, P214S, R220P, Q221P, I242T, Q250H, p.V254del, G260E, G261S, D299E, S304T and P362T.

76. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: R4M/Y207S, A15T, A15G, W24G, G35V, M421, E48Q, N53D, P60S, F69L, M721, G85S, G85N, G104V, L106F, A108T, D109G, G144D, L167V, L180W, G195V, R196G, V199A, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T, K391T, G395E and p.T400_S401dup.

77. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: R4M/Y207S, W24G, G35V, M421, E48Q, N53D, P60S, F69L, G85S, G85N, G104V, L106F, D109G, G144D, L180W, G195V, R196G, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T, K391T, G395E and p.T400_S401dup.

78. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: G35V, M421, F69L and L180W.

79. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: A15T, W24G, G35V, M42I, N53D, P60S, F69L, M72I, G104V, L106F, A108T, G144D, L167V, L180W, G195V, R196G, V199A, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T and K391T.

80. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: W24G, G35V, M42I, N53D, P60S, F69L, G104V, L106F, G144D, L180W, G195V, R196G, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, p.V254del, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T and K391T.

81. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: R4M/Y207S, A15T, A15G, F18C, W24G, N34D, G35V, M42I, E48Q, N53D, P60S, F69L, M72I, G85S, G85N, G104V, L106F, A108T, D109G, R112G, G144D, L167V, L180W, G195V, R196G, V199A, E203D, P210S, P210L, P214S, R220P Q221P, F229L, I242T, W245G, Q250H, G260E, G261S, G271S/D313Y, W277C, D299E, S304T, D313Y/G411D, I319F, F337S, P343L, G361A, P362T, K391T and G395E.

82. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: R4M/Y207S, W24G, G35V, M42I, E48Q, N53D, P60S, F69L, G85S, G85N, G104V, L106F, D109G, G144D, L180W, G195V, R196G, E203D, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, G260E, G261S, W277C, D299E, S304T, I319F, F337S, G361A, P362T, K391T and G395E.

83. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: A15T, F18C, W24G, G35V, M42I, N53D, P60S, F69L, M72I, G104V, L106F, A108T, G144D, L167V, L180W, G195V, R196G, V199A, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, W245G, Q250H, G260E, G261S, W277C, D299E, S304T, I319F, F337S, P343L, G361A, P362T and K391T.

84. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: N53D, P60S, L180W, R196G, P210S, P210L, P214S, R220P, Q221P, I242T, Q250H, G260E, G261S, D299E, S304T and P362T.

85. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: W24G, G35V, M42I, N53D, P60S, F69L, G104V, L106F, G144D, L180W, G195V, R196G, P210S, P210L, P214S, R220P, Q221P, F229L, I242T, Q250H, G260E, G261S, W277C, D299E, S304T, 1319F, F337S, G361A, P362T and K391T.

86. The method of claim 1 , wherein the mutation is selected from the group consisting of: A15T, A15G, F18C, E48Q, F69L, G104V, L106F, A108T, D109G, L167V, G195V, R196G, P210S, P210L, Q221P, F229L, W245G, D299E, F337S, P343L and K391T.

87. The molecule of claim 60 , wherein the mutation is selected from the group consisting of: A15T, A15G, F18C, E48Q, F69L, G104V, L106F, A108T, D109G, L167V, G195V, R196G, P210S, P210L, Q221P, F229L, W245G, D299E, F337S, P343L and K391T.

88. The α-galactosidase A protein of claim 73 , wherein the mutation is selected from the group consisting of: A15T, A15G, F18C, E48Q, F69L, G104V, L106F, A108T, D109G, L167V, G195V, R196G, P210S, P210L, Q221P, F229L, W245G, D299E, F337S, P343L and K391T.

89. The method of claim 1 , wherein the mutation is selected from the group consisting of: N34D, M42I, R196G, V199A, E203D, p. V254del and G260E.

90. The method of claim 1 , wherein the mutation is N34D.

91. The method of claim 1 wherein the mutation is M42I.

92. The method of claim 1 wherein the mutation is R196G.

93. The method of claim 1 wherein the mutation is V199A.

94. The method of claim 1 wherein the mutation is E203D.

95. The method of claim 1 wherein the mutation is V254del.

96. The method of claim 1 wherein the mutation is G260E.

97. The method of claim 1 , wherein the mutation is selected from the group consisting of: R196G, p. V254del and G260E.

Assignments (4)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 075494/0030 →
SECURITY INTEREST Recorded Oct 6, 2023
From: AMICUS THERAPEUTICS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 065177/0196 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2022
From: CASTELLI, JEFF; BENJAMIN, ELFRIDA
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 061099/0803 →